Silo Pharma, Inc.: Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Silo Pharma (Nasdaq: SILO) announced a private placement priced at-the-market under Nasdaq rules for 619,965 shares (or pre-funded warrants) plus Series A-3 and short-term Series A-4 warrants to buy up to 619,965 shares each. Price is $6.452 per share, with $6.21 warrant exercise. Gross proceeds are about $4M upfront, up to $7.7M if warrants are fully exercised in cash. Net proceeds for working capital and general corporate purposes.
How this was made
The 30-second read
Why it matters
The financing provides expected gross proceeds of about $4.0M, with potential additional cash of about $7.7M if warrants are fully exercised. The immediate exercisability and resale registration rights can influence trading around the closing date and subsequent warrant-related flows.
Market read
Traders should price in dilution from the share issuance and monitor warrant overhang and potential exercise-driven cash inflows around the July 10, 2026 close.
What to watch
Warrant terms matter: immediate exercisability and the $6.21 exercise price can create a path to additional cash ($up to ~$7.7M) if the stock trades above the strike and holders exercise.
Background
Silo Pharma is a developmental-stage biopharmaceutical company; this release details a priced private placement with common stock (or pre-funded warrants) and two warrant tranches.
Ticker impact
Silo Pharma announced a private placement priced at-the-market under Nasdaq rules, selling 619,965 shares plus immediately exercisable warrants.
Likely near-term pressure from dilution and warrant overhang, with upside sensitivity if investors view the raise as extending runway without heavy downside risk.
The article discloses the offering size ($4.0M gross expected) and warrant structure (exercise price $6.21, immediate exercisability), which typically weighs on microcap biotech stocks, though the actual impact depends on closing and investor appetite.
Market effects
Adds another example of developmental-stage biotech using at-the-market equity plus warrants, reinforcing financing risk for the group.
No specific regional spillover beyond US microcap biotech financing.
Limited, as the disclosure is company-specific and US-focused (Nasdaq rules, SEC resale registration rights).
Counterpoint
If the company’s cash runway is the binding constraint, the raise could reduce near-term financing risk, which can offset dilution concerns.
Key entities
- issuerSilo Pharma, Inc.
Announced a $4.0M expected gross private placement at-the-market under Nasdaq rules, plus Series A-3 and A-4 warrants.
- placement_agentH.C. Wainwright & Co.
Acting as exclusive placement agent for the offering.
